TipRanks
Krystal Biotech (KRYS)
NASDAQ:KRYS
US Market
KRYS
Krystal Biotech
RESEARCH TOOLSreports
Want to see KRYS full AI Analyst Report?

Krystal Biotech (KRYS) Stock Forecast & Price Target

726 Followers
See the Price Targets and Ratings of:

KRYS Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Krystal
Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KRYS Stock 12 Month Forecast

Average Price Target

$403.50
▲(13.28% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $403.50 with a high forecast of $441.00 and a low forecast of $361.00. The average price target represents a 13.28% change from the last price of $356.19.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"178":"$178","244":"$244","310":"$310","376":"$376","442":"$442"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":441,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$441.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":403.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$403.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":361,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$361.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[178,244,310,376,442],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,325.31,334.20923076923077,343.10846153846154,352.0076923076923,360.9069230769231,369.80615384615385,378.7053846153846,387.6046153846154,396.50384615384615,405.4030769230769,414.3023076923077,423.20153846153846,432.10076923076923,{"y":441,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,325.31,331.3246153846154,337.33923076923077,343.3538461538462,349.36846153846153,355.38307692307694,361.3976923076923,367.4123076923077,373.42692307692306,379.44153846153847,385.4561538461538,391.47076923076924,397.48538461538465,{"y":403.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,325.31,328.05538461538464,330.8007692307692,333.54615384615386,336.29153846153844,339.0369230769231,341.7823076923077,344.5276923076923,347.2730769230769,350.01846153846157,352.76384615384615,355.5092307692308,358.25461538461536,{"y":361,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":179.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":215.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":282.27,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":258.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":258.91,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":266.04,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":371.58,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":341.12,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":363.84,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.31,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$441.00Average Price Target$403.50Lowest Price Target$361.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on KRYS
Yigal Nochomovitz
Citi
Citi
$386→$416
Buy
16.79%
Upside
Reiterated
10/16/26
Krystal Biotech price target raised to $416 from $386 at CitiKrystal Biotech price target raised to $416 from $386 at Citi
H.C. Wainwright Analyst forecast on KRYS
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$361
Buy
1.35%
Upside
Reiterated
10/15/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Krystal Biotech (NASDAQ: KRYS)
RBC Capital Analyst forecast on KRYS
Lisa Walter
RBC Capital
RBC Capital
$400
Buy
12.30%
Upside
Reiterated
10/08/26
RBC Capital Sticks to Its Buy Rating for Krystal Biotech (KRYS)
Goldman Sachs Analyst forecast on KRYS
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$441
Buy
23.81%
Upside
Initiated
09/24/26
Goldman Sachs Resumes Coverage with a Buy Rating on Krystal Biotech (KRYS)
Bank of America Securities Analyst forecast on KRYS
Alec Stranahan
Bank of America Securities
Bank of America Securities
$392→$400
Buy
12.30%
Upside
Reiterated
09/21/26
Krystal Biotech price target raised to $400 from $392 at BofAKrystal Biotech price target raised to $400 from $392 at BofA
Wolfe Research Analyst forecast on KRYS
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS) and Immunic (NASDAQ: IMUX)
TD Cowen Analyst forecast on KRYS
Ritu Baral
TD Cowen
TD Cowen
$403
Buy
13.14%
Upside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP), Supernus Pharmaceuticals (NASDAQ: SUPN) and Krystal Biotech (NASDAQ: KRYS)
William Blair Analyst forecast on KRYS
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/03/26
Analyst Backs Krystal with Buy Rating on Vyjuvek Launch Momentum and Rare-Disease Pipeline Upside
Jefferies Analyst forecast on KRYS
Roger Song
Jefferies
Jefferies
$474
Buy
33.08%
Upside
Assigned
07/13/26
Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Krystal Biotech (NASDAQ: KRYS) and Denali Therapeutics (NASDAQ: DNLI)
Evercore ISI Analyst forecast on KRYS
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$295→$300
Buy
-15.78%
Downside
Reiterated
05/05/26
Krystal Biotech price target raised to $300 from $295 at Evercore ISIKrystal Biotech price target raised to $300 from $295 at Evercore ISI
Guggenheim Analyst forecast on KRYS
Debjit Chattopadhyay
Guggenheim
Guggenheim
$284
Buy
-20.27%
Downside
Reiterated
05/04/26
Guggenheim Sticks to Their Buy Rating for Krystal Biotech (KRYS)
Chardan Capital Analyst forecast on KRYS
Geulah Livshits
Chardan Capital
Chardan Capital
$323
Buy
-9.32%
Downside
Reiterated
05/04/26
Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)
Clear Street Analyst forecast on KRYS
William Maughan
Clear Street
Clear Street
$338→$311
Buy
-12.69%
Downside
Reiterated
05/04/26
Krystal Biotech price target lowered to $311 from $338 at Clear StreetKrystal Biotech price target lowered to $311 from $338 at Clear Street
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on KRYS
Yigal Nochomovitz
Citi
Citi
$386→$416
Buy
16.79%
Upside
Reiterated
10/16/26
Krystal Biotech price target raised to $416 from $386 at CitiKrystal Biotech price target raised to $416 from $386 at Citi
H.C. Wainwright Analyst forecast on KRYS
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$361
Buy
1.35%
Upside
Reiterated
10/15/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Krystal Biotech (NASDAQ: KRYS)
RBC Capital Analyst forecast on KRYS
Lisa Walter
RBC Capital
RBC Capital
$400
Buy
12.30%
Upside
Reiterated
10/08/26
RBC Capital Sticks to Its Buy Rating for Krystal Biotech (KRYS)
Goldman Sachs Analyst forecast on KRYS
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$441
Buy
23.81%
Upside
Initiated
09/24/26
Goldman Sachs Resumes Coverage with a Buy Rating on Krystal Biotech (KRYS)
Bank of America Securities Analyst forecast on KRYS
Alec Stranahan
Bank of America Securities
Bank of America Securities
$392→$400
Buy
12.30%
Upside
Reiterated
09/21/26
Krystal Biotech price target raised to $400 from $392 at BofAKrystal Biotech price target raised to $400 from $392 at BofA
Wolfe Research Analyst forecast on KRYS
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS) and Immunic (NASDAQ: IMUX)
TD Cowen Analyst forecast on KRYS
Ritu Baral
TD Cowen
TD Cowen
$403
Buy
13.14%
Upside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP), Supernus Pharmaceuticals (NASDAQ: SUPN) and Krystal Biotech (NASDAQ: KRYS)
William Blair Analyst forecast on KRYS
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/03/26
Analyst Backs Krystal with Buy Rating on Vyjuvek Launch Momentum and Rare-Disease Pipeline Upside
Jefferies Analyst forecast on KRYS
Roger Song
Jefferies
Jefferies
$474
Buy
33.08%
Upside
Assigned
07/13/26
Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Krystal Biotech (NASDAQ: KRYS) and Denali Therapeutics (NASDAQ: DNLI)
Evercore ISI Analyst forecast on KRYS
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$295→$300
Buy
-15.78%
Downside
Reiterated
05/05/26
Krystal Biotech price target raised to $300 from $295 at Evercore ISIKrystal Biotech price target raised to $300 from $295 at Evercore ISI
Guggenheim Analyst forecast on KRYS
Debjit Chattopadhyay
Guggenheim
Guggenheim
$284
Buy
-20.27%
Downside
Reiterated
05/04/26
Guggenheim Sticks to Their Buy Rating for Krystal Biotech (KRYS)
Chardan Capital Analyst forecast on KRYS
Geulah Livshits
Chardan Capital
Chardan Capital
$323
Buy
-9.32%
Downside
Reiterated
05/04/26
Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)
Clear Street Analyst forecast on KRYS
William Maughan
Clear Street
Clear Street
$338→$311
Buy
-12.69%
Downside
Reiterated
05/04/26
Krystal Biotech price target lowered to $311 from $338 at Clear StreetKrystal Biotech price target lowered to $311 from $338 at Clear Street
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OVIDOvid Therapeutics
AXGNAxoGen
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
REPLReplimune Group
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Krystal Biotech

3 Months
Geulah LivshitsChardan Capital
Success Rate
13/20 ratings generated profit
65%
Average Return
+11.04%
Copying Geulah Livshits's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +11.04% per trade.
1 Year
Geulah LivshitsChardan Capital
Success Rate
19/20 ratings generated profit
95%
Average Return
+49.15%
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +49.15% per trade.
2 Years
Geulah LivshitsChardan Capital
Success Rate
20/20 ratings generated profit
100%
Average Return
+96.27%
Copying Geulah Livshits's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +96.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KRYS Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
19
20
12
11
11
Hold
0
0
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
20
13
12
12
In the current month, KRYS has received 11 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KRYS average Analyst price target in the past 3 months is 403.50.
Each month's total comprises the sum of three months' worth of ratings.

KRYS Financial Forecast

KRYS Earnings Forecast

Next quarter’s earnings estimate for KRYS is $1.83 with a range of $1.60 to $2.15. The previous quarter’s EPS was $1.79. KRYS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KRYS has Performed in-line its overall industry.
Next quarter’s earnings estimate for KRYS is $1.83 with a range of $1.60 to $2.15. The previous quarter’s EPS was $1.79. KRYS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KRYS has Performed in-line its overall industry.

KRYS Sales Forecast

Next quarter’s sales forecast for KRYS is $126.77M with a range of $122.80M to $134.40M. The previous quarter’s sales results were $119.22M. KRYS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KRYS has Performed in-line its overall industry.
Next quarter’s sales forecast for KRYS is $126.77M with a range of $122.80M to $134.40M. The previous quarter’s sales results were $119.22M. KRYS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KRYS has Performed in-line its overall industry.

KRYS Stock Forecast FAQ

What is KRYS’s average 12-month price target, according to analysts?
Based on analyst ratings, Krystal Biotech’s 12-month average price target is 403.50.
    What is KRYS’s upside potential, based on the analysts’ average price target?
    Krystal Biotech has 13.28% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KRYS a Buy, Sell or Hold?
          Krystal Biotech has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Krystal Biotech’s price target?
            The average price target for Krystal Biotech is 403.50. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $441.00 ,the lowest forecast is $361.00. The average price target represents 13.28% Increase from the current price of $356.19.
              What do analysts say about Krystal Biotech?
              Krystal Biotech’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of KRYS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.